Search

everythinglearnresearchcommunity

for

Search:↓

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

User shared progress pictures showing hair growth from January to March using 1mg finasteride, topical minoxidil with peppermint oil, derma stamping twice a week, and biotin. Commenters are impressed with the quick and significant improvement.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.

The user plans to pause finasteride for two months to test its effects on mood and productivity, then switch to Pyrilutamide while monitoring hormone levels. Concerns are raised about potential hair loss and the effectiveness of Pyrilutamide compared to finasteride.

Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.

The user experiences scalp inflammation, especially when oily, despite using treatments like dutasteride, oral minoxidil, RU58841, and nizoral. They recently started cetirizine and are considering benzoyl peroxide wash for relief.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The user has been using 1 mg finasteride, topical minoxidil twice daily, 1 biotin vitamin, and a 0.5 mm dermaroller for hair loss treatment since April. They've seen progress but experienced a shedding event in October, and are hoping for increased density in the coming months.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The conversation discusses using Pyrilutamide 1% as a potential treatment for hair loss, with some users combining it with minoxidil and finasteride. Experiences vary, with some reporting shedding and no progress, while others remain hopeful for future results.